1-4 of 4
Teresa Melink
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma

Free
Haitham Abdelhakim, Geoffrey Shouse, Manali Kamdar, Priyanka Pophali, Samuel Yamshon, Luke Mountjoy, Aravind Ramakrishnan, Ian Flinn, Akiva Diamond, Margaret Gilbert, Maria-Bernadette Madel, Laura Angelo, Hettie Stein, Deb Chapman, Patricia Allison, John Gutheil, Teresa Melink, Susie Bergman, Mary Newman, Helen Heslop, Malcolm Brenner, Premal Lulla, Monic Stuart, Juan Vera
Journal: Blood
Blood (2025) 146 (Supplement 1): 1846.
https://doi.org/10.1182/blood-2025-1846
Published: 2025
Journal Articles

MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)

Free
Geoffrey Shouse, Samuel Yamshon, Manali Kamdar, Haitham Abdelhakim, Priyanka Pophali, Luke Mountjoy, Aravind Ramakrishnan, Ian Flinn, Akiva Diamond, Margaret Gilbert, Maria-Bernadette Madel, Laura Angelo, Hettie Stein, Deb Chapman, Patricia Allison, John Gutheil, Teresa Melink, Susie Bergman, Mary Newman, Helen Heslop, Malcolm Brenner, Premal Lulla, Monic Stuart, Juan Vera
Journal: Blood
Blood (2025) 146 (Supplement 1): 5944.
https://doi.org/10.1182/blood-2025-5944
Published: 2025
Journal Articles

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Free
Arnold S. Freedman, MD, Paul A. Hamlin, MD, Sattva Neelapu, MD, Craig Nichols, MD, Michael Robertson, MD, Gregoire Bergier, MD, Jane N. Winter, MD, Jonathan Polikoff, MD, Thomas Lin, MD, PhD, Brad Pohlman, MD, Vanessa Esquibel, Teresa Melink, NP, John Bender, PharmD
Journal: Blood
Blood (2006) 108 (11): 2756.
https://doi.org/10.1182/blood.V108.11.2756.2756
Published: 2006
Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Free
Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD
Journal: Blood
Blood (2006) 108 (11): 691.
https://doi.org/10.1182/blood.V108.11.691.691
Published: 2006